Daily Archives: May 5, 2022

Fam-trastuzumab deruxtecan-nxki is approved by FDA for breast cancer

May 5th, 2022 Breast Cancer

April 2022: Adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recu.... Read More

Pluvicto is approved by FDA for metastatic castration-resistant prostate cancer

May 5th, 2022 Prostrate cancer

April 2022: The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patients with prostate-specific membrane antigen (.... Read More

Pembrolizumab is approved for advanced endometrial carcinoma

May 5th, 2022 Cancer, Endometrial cancer, Immunotherapy

April 2022: Pembrolizumab (Keytruda, Merck) was approved by the Food and Drug Administration as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR),.... Read More